A Study of BGB-311 Plus Anti-CD20's

Trial ID:
IRB-23-8225
Marin Xavier, MD

Inclusion Criteria

Patients must:

  • Have histologically confirmed grade 1-3a Follicular or Marginal Zone Lymphoma.
    Have been previously treated with at least one line of systemic therapy including anti-CD20mAbs.

Exclusion Criteria

Patients must not:

  • Have central nervous system involvement.
    Have prior BTK inhibitor or Lenalidomide treatment.
    Have an ongoing need for corticosteroid treatment (adrenal replacement are eligible).
    Have any significant cardiovascular disease.
    Have had any prior malignancies in the past 2 years.

Additional Info

*An additional tissue/bone marrow biopsy may be required.

*All treatments and physician visits during this study will take place at Scripps Clinic Torrey Pines (Geisel Pavilion) or Scripps Prebys Cancer Center

*Study participation could last up to 2.5 years

*Search NCT05100862 at https://clinicaltrials.gov website for more information.

Contact Info:

  • Clinical Research Services”
  • CRSLeadership@scrippshealth.org